The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Obinutuzumab increases survival in CLL patients with comorbidities
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic lymphocytic leukemia (CLL) in elderly patients with multiple comorbidities. Michael Hallek, PhD, of CECAD Cologne, Cologne, Germany, presented the final follow-up results from this trial at the 23rd Congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden. These results showed a surprising improvement in overall survival with obinutuzumab/chlorambucil compared to rituximab/chlorambucil, suggesting that obinutuzumab confers a survival benefit even in high-risk patients with multiple comorbidities. Prof. Hallek points to obinutuzumab as the new standard of care for unfit elderly CLL patients.
